Pedro Barata is joined by Brian Shuch to discuss his investigator-initiated phase 2 trial evaluating girentuximab PET-CT imaging for detecting residual disease after nephrectomy in clear cell renal ...

At the World Congress of Endourology and Uro-Technology, Kriselle Madamba presented research on antibiotic-augmented irrigation using neomycin and polymyxin B during ureteroscopy to reduce ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Read the Full Video Transcript Andrea Miyahira: Hi, everyone. I'm Andrea Miyahira with the Prostate Cancer Foundation. Thank you for joining me for a special Women in Science episode. And joining me ...

Eric Kim interviews Aaron Berger about treatment approaches for high-risk prostate cancer and biochemical recurrence. Dr. Berger explains his balanced approach to treatment selection between surgery ...

At the 2025 UCSF-UCLA PSMA Conference, Tanya Stoyanova discusses TROP2 as a promising alternative target for prostate cancer imaging and radiotherapy. She highlights that 25% of metastatic ...

Login to update email address, newsletter preferences and use bookmarks.

Read the Full Video Transcript Ashish Kamat: Hello everybody, and welcome to UroToday's Bladder Cancer Center of Excellence. I'm Ashish Kamat, professor of urologic oncology at M.D. Anderson Cancer ...

At the 2025 UCSF-UCLA PSMA Conference, Matthias Eiber discusses lutetium PSMA therapy beyond six standard cycles. He distinguishes between extended treatment (continuous administration) and ...

At the 2025 UCSF-UCLA PSMA Conference, Daniel Spratt presents on bone scan obsolescence in prostate cancer imaging. He demonstrates they fail to detect cancer with sufficient sensitivity compared to ...

Zachary Klaassen speaks with Alicia Morgans about examining the impact of PSA doubling time awareness on treatment decisions for high-risk biochemical recurrence. Dr. Morgans discusses findings from a ...